Raft
Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases
Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement
Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases
Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification